Glimcloud-M4 SR Tablet is a combination oral hypoglycemic agent containing Glimepiride 4 mg and Metformin 500 mg, formulated for sustained release to optimize glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving peripheral insulin sensitivity, and enhancing glucose uptake in muscle tissues. The synergistic action of these two agents addresses multiple pathophysiological defects of type 2 diabetes, promoting effective blood sugar regulation. Glimcloud-M4 SR is indicated as an adjunct to diet and exercise to improve glycemic control in patients inadequately controlled on monotherapy or lifestyle modifications alone. The sustained-release formulation ensures a gradual release of metformin, minimizing gastrointestinal side effects commonly associated with immediate-release forms and improving patient compliance. Dosage should be individualized based on patient response and tolerability, with regular monitoring of blood glucose and renal function recommended. Contraindications include severe renal impairment, metabolic acidosis, and hypersensitivity to either component. This combination therapy should be used cautiously in patients with hepatic dysfunction or cardiovascular disease.